OOIR: Observatory of International Research

Papers

(The H4-Index of Drug Discovery Today is 52. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Can drug production be democratized?	809120313
Artificial intelligence in drug discovery and development	466
Role of oxidative stress in depression	268
Recent discovery and development of inhibitors targeting coronaviruses	256
Fsp3: A new parameter for drug-likeness	151
Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management	140
Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet	131
Potential SARS-CoV-2 main protease inhibitors	119
High-Throughput Screening: today’s biochemical and cell-based approaches	114
Epitope-based vaccine design: a comprehensive overview of bioinformatics approaches	113
3D printing for drug delivery and biomedical applications	112
Zeolites in drug delivery: Progress, challenges and opportunities	109
Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective	107
De novo molecular design and generative models	103
Machine learning models for drug–target interactions: current knowledge and future directions	101
Advancing computer-aided drug discovery (CADD) by big data and data-driven machine learning modeling	99
Comparison of DNA and mRNA vaccines against cancer	99
Machine-learning methods for ligand–protein molecular docking	96
The combination of disulfiram and copper for cancer treatment	93
Bayer’s in silico ADMET platform: a journey of machine learning over the past two decades	89
Fundamental aspects of DMPK optimization of targeted protein degraders	86
Ionic liquids: green and tailor-made solvents in drug delivery	84
Theranostic application of nanoemulsions in chemotherapy	84
Challenges and hopes for Alzheimer’s disease	83
Application of mesoporous silica nanoparticles as drug delivery carriers for chemotherapeutic agents	83

Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects	82
Discovering small-molecule therapeutics against SARS-CoV-2	82
Prussian blue nanoparticles: synthesis, surface modification, and biomedical applications	79
Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 2: a discussion of chemical and biological data	77
Advanced machine-learning techniques in drug discovery	76
Déjà vu: Stimulating open drug discovery for SARS-CoV-2	73
Role of reactive oxygen species in the progression of Alzheimer’s disease	70
Graph neural networks for automated de novo drug design	70
Advanced glycation end products in diabetes, cancer and phytochemical therapy	69
Recent advances in targeted nanomedicine as promising antitumor therapeutics	67
Exploring chemical space using natural language processing methodologies for drug discovery	66
Recent advances in metabolomics analysis for early drug development	64
Covalent fragment libraries in drug discovery	64
Drug combination therapy for emerging viral diseases	63
Gold nanoparticles: synthesis, physiochemical properties and therapeutic applications in cancer	63
Synthesis and modification of bio-derived antibacterial Ag and ZnO nanoparticles by plants, fungi, and bacteria	61
New perspectives in oral peptide delivery	60
Recent advances in nano delivery systems for blood-brain barrier (BBB) penetration and targeting of brain tumors	60
COVID-19 and pneumonia: a role for the uPA/uPAR system	59
Chloroquine against malaria, cancers and viral diseases	58
Nanovehicles for co-delivery of anticancer agents	58
The multifunctional APE1 DNA repair–redox signaling protein as a drug target in human disease	58
Advances in antibody phage display technology	57
Recent developments in pharmaceutical salts: FDA approvals from 2015 to 2019	55
Converting peptides into drugs targeting intracellular protein–protein interactions	53
Fragment-based drug discovery using cryo-EM	53
PepTherDia: database and structural composition analysis of approved peptide therapeutics and diagnostics	52